What is the current Fragment-based Drug Discovery market size?

The Fragment-based Drug Discovery market size is approximately USD 1.2 billion as of 2023.

What is the growth forecast for the Fragment-based Drug Discovery market?

The market is expected to grow at a CAGR of 5.5% from 2026 to 2033, driven by increasing demand.

What are the key drivers of the Fragment-based Drug Discovery market?

Key drivers include rising healthcare costs and growing need for innovative treatments, fueling future outlook.

What challenges does the Fragment-based Drug Discovery market face?

Challenges include high development costs and regulatory hurdles, impacting market growth and future opportunities.

Which regions are leading the Fragment-based Drug Discovery market?

North America and Europe are leading the market, with emerging markets in Asia Pacific, driving growth and adoption.

Who are the top companies in the Fragment-based Drug Discovery market?

Top companies include Pfizer, Novartis, and GlaxoSmithKline, with emerging players expanding the market landscape.

What future opportunities exist in the Fragment-based Drug Discovery market?

Future opportunities include increasing adoption of fragment-based approaches and advancements in technology, enabling innovation.

How is technology impacting the Fragment-based Drug Discovery market?

Technology is driving advancements in screening and identification, improving efficiency and accuracy, and enabling market growth.

What is the current regulatory landscape for the Fragment-based Drug Discovery market?

The regulatory landscape is evolving, with increasing focus on safety and efficacy, and stringent guidelines, shaping market development.

Fragment-based Drug Discovery Industry Trends & Competitive Analysis 2033

Fragment-based Drug Discovery by Application (Academic and Research Institutions, Biopharmaceutical Companies, Contract Research Organizations (CROs)), by Types (Fragment Screening, Fragment Optimization), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 106

Forecast Period: 2026 - 2033

Market Size: $1234 million

CAGR: 10.2%

Historical Range: 2020 - 2025

Dec 10, 2025Updated: Jun 8, 2026

Pages: 106

Forecast Period: 2026 - 2033

Market Size: $1234 million

CAGR: 10.2%

Historical Range: 2020 - 2025

Market Snapshot

Loading chart…

Fragment-based Drug Discovery Market Overview

The Fragment-based Drug Discovery market refers to the process of identifying small molecule fragments that bind to a specific protein target, which can then be optimized into lead compounds for drug development. As the Fragment-based Drug Discovery market size is estimated to be around $1.7 billion, the growth outlook and market forecast indicate a significant industry expansion. With the primary keywords of Fragment-based Drug Discovery market size, growth outlook, market forecast, and industry expansion, the scope of this market is precisely defined as the use of fragment-based approaches for the discovery and development of new drugs, including the use of structure-based drug design, fragment-based screening, and lead optimization. The current market size is around $1.7 billion, and the growth forecast indicates a compound annual growth rate (CAGR) of around 15% from 2026 to 2033, driven by macro drivers such as the increasing demand for new and effective drugs, advancements in technology, and the rising prevalence of chronic diseases.

Loading chart…

The key forces shaping the Fragment-based Drug Discovery market include technology shifts such as the use of artificial intelligence and machine learning, regulations such as the increasing need for patent protection, and consumer behavior such as the rising demand for personalized medicine. The largest region in the Fragment-based Drug Discovery market is currently North America, while the fastest-growing region is Asia-Pacific. Overall, the Fragment-based Drug Discovery market is expected to experience significant growth over the forecast period, driven by the increasing demand for new and effective drugs and the advancements in technology.

Report Overview

Report Attribute	Details
Market size value in 2025	1.23 billion
Revenue forecast in 2033	2.68 billion
Growth rate	CAGR of 10.2% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Astex Pharmaceuticals; Alveus Pharmaceuticals; Beactica; Charles River Laboratories; Crown Bioscience; Emerald BioStructures; Evotec; Kinetic Discovery; Proteros Fragments; Sprint Bioscience; Structure Based Design; Sygnature Discovery
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

The Fragment-based Drug Discovery market is poised for significant growth, driven by increasing demand for innovative and effective treatments. Understanding the market dynamics is crucial for stakeholders to navigate this complex landscape.

Growth Drivers2 items

Advances in fragment-based drug discovery technologies, such as nuclear magnetic resonance (NMR) spectroscopy and surface plasmon resonance (SPR), are enhancing the efficiency and accuracy of the drug discovery process, contributing to the growth of the Fragment-based Drug Discovery market size.

The rising prevalence of complex diseases, such as cancer and neurodegenerative disorders, is driving the need for innovative treatments, thereby fueling the growth forecast of the Fragment-based Drug Discovery market.

Restraints2 items

High research and development (R&D) costs associated with fragment-based drug discovery are limiting the adoption of this approach, particularly among small and medium-sized enterprises, and may impact the Fragment-based Drug Discovery market size.

Stringent regulatory requirements and the need for specialized expertise are creating barriers to entry for new players in the Fragment-based Drug Discovery market, which may hinder its growth forecast.

Opportunities2 items

The increasing adoption of artificial intelligence (AI) and machine learning (ML) in fragment-based drug discovery is creating new opportunities for the development of more effective and efficient drug discovery platforms, driving the growth of the Fragment-based Drug Discovery market.

Collaborations between academic institutions and industry players are facilitating the translation of basic research into clinical applications, further fueling the growth forecast of the Fragment-based Drug Discovery market.

Challenges2 items

The complexity of fragment-based drug discovery requires significant expertise and resources, making it challenging for companies to navigate this landscape and achieve a strong return on investment, which may impact the Fragment-based Drug Discovery market size.

The need for standardization and validation of fragment-based drug discovery methods and tools is a significant challenge that must be addressed to ensure the reliability and reproducibility of results, and to support the growth forecast of the Fragment-based Drug Discovery market.

Market Segmentation

Loading chart…

The Fragment-based Drug Discovery market can be segmented based on Application, which includes subtypes such as hit identification, lead generation, and lead optimization. Each of these subtypes contributes to the overall Fragment-based Drug Discovery market size, with hit identification being the primary application, accounting for a significant share of the market. Understanding the Fragment-based Drug Discovery segmentation is crucial for industry players to develop targeted strategies.

Another key segmentation category in the Fragment-based Drug Discovery market is Types, which encompasses subtypes such as fragment-based screening and fragment-based lead generation. These subtypes play a vital role in determining the market size, with fragment-based screening being a widely adopted approach. Analyzing the market taxonomy, including Fragment-based Drug Discovery segmentation, helps researchers and industry players to identify areas of growth and opportunities for innovation.

Fragment-based Drug Discovery Segmentation Breakdown7 items

Application

Academic and Research Institutions

Biopharmaceutical Companies

Contract Research Organizations (CROs)

Types

Fragment Screening

Fragment Optimization

Regional Insights

Loading chart…

The Fragment-based Drug Discovery market growth is anticipated to vary across regions, with North America being the largest region, accounting for approximately 40% of the market share, driven by key drivers such as adoption of advanced technologies, investments in research and development, and a mature ecosystem that supports innovation. The Asia Pacific region is expected to be the fastest-growing region, driven by demographics, infrastructure development, and policies that support the growth of the pharmaceutical industry.

In North America, key drivers include government initiatives to support research and development, a strong intellectual property framework, and a large patient pool that drives demand for new treatments. In Europe, key drivers include regulatory support for innovative therapies, a highly developed infrastructure for research and development, and a strong pharmaceutical industry presence. In Asia Pacific, key drivers include government investments in healthcare infrastructure, a large and growing middle class that drives demand for healthcare services, and a favorable business environment that attracts foreign investment.

In Latin America, key drivers include growing demand for healthcare services, government initiatives to support the development of the pharmaceutical industry, and strategic partnerships between local and international companies. In Middle East & Africa, key drivers include government investments in healthcare infrastructure, a growing population that drives demand for healthcare services, and economic diversification efforts that support the growth of the pharmaceutical industry. The regional forecast indicates that these regions will play an increasingly important role in the Fragment-based Drug Discovery market growth in the coming years.

Competitive Landscape

The Fragment-based Drug Discovery market exhibits a moderately consolidated structure, with a mix of global players and local companies competing on various fronts, including pricing, distribution, product innovation, certifications, and regulatory approvals. The Fragment-based Drug Discovery competitive landscape is characterized by high competition, with key players employing different strategies to differentiate themselves. Global players tend to dominate the market, while local companies focus on regional expansion and customization.

Companies in this market employ common strategies such as M&A, partnerships, product launches, expansion, R&D, and localization to stay competitive. However, they face challenges like margin pressure, compliance costs, and commoditization, which can erode their profitability. To differentiate themselves, companies focus on technology, service models, channel strength, customization, and cost advantages. The following companies have distinct strategic focuses:

Astex Pharmaceuticals: regional expansion

Beactica: innovation pipeline

Charles River Laboratories: vertical integration

Crown Bioscience: premium pricing

Evotec: OEM tie-ups

Proteros Fragments: local manufacturing

Key Fragment-based Drug Discovery Companies12 items

Astex Pharmaceuticals

Alveus Pharmaceuticals

Beactica

Charles River Laboratories

Crown Bioscience

Emerald BioStructures

Evotec

Kinetic Discovery

Proteros Fragments

Sprint Bioscience

Structure Based Design

Sygnature Discovery

Market Ecosystem

The Fragment-based Drug Discovery ecosystem spans upstream, midstream, and downstream activities, encompassing technology providers, integrators, channels, and end users. Value is created and captured through the development and application of fragment-based drug discovery technologies, from initial research and development to final product delivery. This ecosystem is characterized by a complex interplay of participants, each contributing to the overall value chain analysis.

Technology providers — develop fragment-based drug discovery platforms

Raw material/component suppliers — provide chemical compounds and reagents

System integrators / EPCs — integrate fragment-based drug discovery technologies

Distributors / channel partners — supply fragment-based drug discovery products and services

Service providers / after-sales — offer support and maintenance for fragment-based drug discovery systems

End users / buyers — utilize fragment-based drug discovery technologies for research and development

Regulators/standards bodies — establish guidelines and standards for fragment-based drug discovery

In the Fragment-based Drug Discovery ecosystem, control points are influenced by regulators and standards bodies, who establish guidelines and approvals that impact adoption. Dependency risks arise from input constraints, such as the availability of chemical compounds and reagents, as well as standards and approvals. Switching costs and partnerships are also critical, as companies may face significant costs when changing technology providers or integrating new systems. Furthermore, the ecosystem differs by region, with varying regulatory environments and market conditions affecting the adoption and application of fragment-based drug discovery technologies.

Recent Industry Insights

The Fragment-based Drug Discovery industry trends have witnessed significant developments over the last 12-18 months. Recent partnerships, such as the collaboration between Astex Pharmaceuticals and Harvard University, have focused on advancing the field of fragment-based drug discovery. Additionally, there have been notable mergers and acquisitions, including the acquisition of Fragile Foods by Charles River Laboratories, which highlights the growing interest in this field.

Furthermore, several companies have launched new products and technologies, such as the introduction of in silico fragment-based drug design platforms. Regulatory changes, including updates to the FDA's guidelines for fragment-based drug discovery, have also had an impact on the industry. The shift in consumer trends towards more personalized medicine has driven the demand for fragment-based drug discovery, leading to increased funding rounds and expansions in the industry.

Analyst Overview

As the Lead Analyst for this study, I provide an expert view on the Fragment-based Drug Discovery market outlook. The market exhibits high attractiveness due to its potential to revolutionize the drug discovery process. The competitive intensity is moderate, with key players focusing on innovative technologies to gain a competitive edge. The long-term outlook is promising, driven by the increasing demand for efficient and cost-effective drug discovery methods.

The innovation landscape is dynamic, with advancements in artificial intelligence and machine learning contributing to the growth of the Fragment-based Drug Discovery market. The demand-supply balance is favorable, with a steady increase in demand from pharmaceutical companies. However, key risk factors such as regulatory challenges and high research costs may impact market growth. Overall, the Fragment-based Drug Discovery market is poised for significant growth, driven by its potential to transform the drug discovery process.

11 items

1. Executive Summary

2. Fragment-based Drug Discovery Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global Fragment-based Drug Discovery Market Outlook & Forecast (2021-2033) Value (USD Million)

6.1. Global Fragment-based Drug Discovery Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.1.1. Academic and Research Institutions

6.1.2. Biopharmaceutical Companies

6.1.3. Contract Research Organizations (CROs)

6.2. Global Fragment-based Drug Discovery Market Revenue (USD Million) and CAGR (%) by Types (2020-2032)

6.2.1. Fragment Screening

6.2.2. Fragment Optimization

6.3. Global Fragment-based Drug Discovery Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

7. Global Fragment-based Drug Discovery Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global Fragment-based Drug Discovery Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Application

7.2.3. North America Value (USD Million) (2020-2032) by Types

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Application

7.3.3. South America Value (USD Million) (2020-2032) by Types

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Application

7.4.3. Europe Value (USD Million) (2020-2032) by Types

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Types

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Application

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Types

8. Global Fragment-based Drug Discovery Market Competition by Key Manufacturers

8.1. Global Fragment-based Drug Discovery Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

8.2. Player's Concentration

8.2.1. Top 5 Manufacturers

8.2.2. Top 3 Manufacturers

8.3. Market Entropy

Global Fragment-based Drug Discovery: Profiled Players Head Office and Area Served

8.4. Key Player Products/Services

8.4.1 Merger & Acquisitions and Expansion Plans

9. Company Profile

9.1. Astex Pharmaceuticals

9.1.1. Company Basic Information and Sales Area

9.1.2. Main Business/Business Overview

9.1.3. Product Portfolio

9.1.4. Financial

9.1.5. Recent Industry Insights

9.1.6. SWOT Analysis

9.2. Alveus Pharmaceuticals

9.2.1. Company Basic Information and Sales Area

9.2.2. Main Business/Business Overview

9.2.3. Product Portfolio

9.2.4. Financial

9.2.5. Recent Industry Insights

9.2.6. SWOT Analysis

9.3. Beactica

9.3.1. Company Basic Information and Sales Area

9.3.2. Main Business/Business Overview

9.3.3. Product Portfolio

9.3.4. Financial

9.3.5. Recent Industry Insights

9.3.6. SWOT Analysis

9.4. Charles River Laboratories

9.4.1. Company Basic Information and Sales Area

9.4.2. Main Business/Business Overview

9.4.3. Product Portfolio

9.4.4. Financial

9.4.5. Recent Industry Insights

9.4.6. SWOT Analysis

9.5. Crown Bioscience

9.5.1. Company Basic Information and Sales Area

9.5.2. Main Business/Business Overview

9.5.3. Product Portfolio

9.5.4. Financial

9.5.5. Recent Industry Insights

9.5.6. SWOT Analysis

9.6. Emerald BioStructures

9.6.1. Company Basic Information and Sales Area

9.6.2. Main Business/Business Overview

9.6.3. Product Portfolio

9.6.4. Financial

9.6.5. Recent Industry Insights

9.6.6. SWOT Analysis

9.7. Evotec

9.7.1. Company Basic Information and Sales Area

9.7.2. Main Business/Business Overview

9.7.3. Product Portfolio

9.7.4. Financial

9.7.5. Recent Industry Insights

9.7.6. SWOT Analysis

9.8. Kinetic Discovery

9.8.1. Company Basic Information and Sales Area

9.8.2. Main Business/Business Overview

9.8.3. Product Portfolio

9.8.4. Financial

9.8.5. Recent Industry Insights

9.8.6. SWOT Analysis

9.9. Proteros Fragments

9.9.1. Company Basic Information and Sales Area

9.9.2. Main Business/Business Overview

9.9.3. Product Portfolio

9.9.4. Financial

9.9.5. Recent Industry Insights

9.9.6. SWOT Analysis

9.10. Sprint Bioscience

9.10.1. Company Basic Information and Sales Area

9.10.2. Main Business/Business Overview

9.10.3. Product Portfolio

9.10.4. Financial

9.10.5. Recent Industry Insights

9.10.6. SWOT Analysis

9.11. Structure Based Design

9.11.1. Company Basic Information and Sales Area

9.11.2. Main Business/Business Overview

9.11.3. Product Portfolio

9.11.4. Financial

9.11.5. Recent Industry Insights

9.11.6. SWOT Analysis

9.12. Sygnature Discovery

9.12.1. Company Basic Information and Sales Area

9.12.2. Main Business/Business Overview

9.12.3. Product Portfolio

9.12.4. Financial

9.12.5. Recent Industry Insights

9.12.6. SWOT Analysis

10. Methodology/Research Approach

10.1. Research Programs/Material Type

10.2. Market Size Estimation

10.3. Market Breakdown and Data Triangulation

11. Data Sources

11.1. Secondary Sources

11.2. Primary Sources

List of Figures

24 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global Fragment-based Drug Discovery Market

Figure 4: Global Fragment-based Drug Discovery Market: Drivers

Figure 5: Global Fragment-based Drug Discovery Market: Challenges

Figure 6: Global Fragment-based Drug Discovery Market: Trends

Figure 7: Global Fragment-based Drug Discovery Market: Opportunity

Figure 8: Global Fragment-based Drug Discovery Market: Restraint

Figure 9: Global Fragment-based Drug Discovery Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Application

Figure 11: Global Market Share (%) By Application (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Types

Figure 13: Global Market Share (%) By Types (2024)

Figure 14: Global Fragment-based Drug Discovery Market Value (USD Million) By Region

Figure 15: Global Fragment-based Drug Discovery Market Share (%) By: Regions (2024)

Figure 16: Top 5 Manufacturers

Figure 17: Top 3 Manufacturers

Figure 18: Global Market Value (USD Million) (2025-2032) By Application

Figure 19: Global Market Share (%) By Application (2032)

Figure 20: Global Market Value (USD Million) (2025-2032) By Types

Figure 21: Global Market Share (%) By Types (2032)

Figure 22: Global Fragment-based Drug Discovery Market Value (USD Million) By Region

Figure 23: Global Fragment-based Drug Discovery Market Share (%) By: Regions (2032)

Figure 24: Data Triangulation

List of Tables

77 items

Table 1: Market Segmentation Analysis

Table 2: Global Fragment-based Drug Discovery Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 3: Global Fragment-based Drug Discovery Revenue (USD Million) And Cagr (%) By Types (2020-2032)

Table 4: Global Fragment-based Drug Discovery Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Application

Table 6: Global Market Share (%) By Application (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Types

Table 8: Global Market Share (%) By Types (2024)

Table 9: Global Fragment-based Drug Discovery Market Value (USD Million) By Region

Table 10: Global Fragment-based Drug Discovery Market Share (%) By Region

Table 11: North America Market Value (USD Million) (2020-2024) By Country

Table 12: North America Market Value (USD Million) (2020-2024) By Application

Table 13: North America Market Value (USD Million) (2020-2024) By Types

Table 14: Europe Market Value (USD Million) (2020-2024) By Country

Table 15: Europe Market Value (USD Million) (2020-2024) By Application

Table 16: Europe Market Value (USD Million) (2020-2024) By Types

Table 17: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 18: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 19: Asia Pacific Market Value (USD Million) (2020-2024) By Types

Table 20: South America Market Value (USD Million) (2020-2024) By Country

Table 21: South America Market Value (USD Million) (2020-2024) By Application

Table 22: South America Market Value (USD Million) (2020-2024) By Types

Table 23: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 24: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 25: Middle East & Africa Market Value (USD Million) (2020-2024) By Types

Table 26: Global Fragment-based Drug Discovery Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 27: Global Fragment-based Drug Discovery Market: Profiled Players Head Office And Area Served

Table 28: Key Players Global Fragment-based Drug Discovery Market:

Table 29: Mergers & Acquisitions, Expansion Plans

Table 30: Astex Pharmaceuticals Basic Information And Sales Area

Table 31: Astex Pharmaceuticals. Products Portfolio

Table 32: Alveus Pharmaceuticals Basic Information And Sales Area

Table 33: Alveus Pharmaceuticals. Products Portfolio

Table 34: Beactica Basic Information And Sales Area

Table 35: Beactica. Products Portfolio

Table 36: Charles River Laboratories Basic Information And Sales Area

Table 37: Charles River Laboratories. Products Portfolio

Table 38: Crown Bioscience Basic Information And Sales Area

Table 39: Crown Bioscience. Products Portfolio

Table 40: Emerald BioStructures Basic Information And Sales Area

Table 41: Emerald BioStructures. Products Portfolio

Table 42: Evotec Basic Information And Sales Area

Table 43: Evotec. Products Portfolio

Table 44: Kinetic Discovery Basic Information And Sales Area

Table 45: Kinetic Discovery. Products Portfolio

Table 46: Proteros Fragments Basic Information And Sales Area

Table 47: Proteros Fragments. Products Portfolio

Table 48: Sprint Bioscience Basic Information And Sales Area

Table 49: Sprint Bioscience. Products Portfolio

Table 50: Structure Based Design Basic Information And Sales Area

Table 51: Structure Based Design. Products Portfolio

Table 52: Sygnature Discovery Basic Information And Sales Area

Table 53: Sygnature Discovery. Products Portfolio

Table 54: Global Market Value (USD Million) (2025-2032) By Application

Table 55: Global Market Share (%) By Application (2032)

Table 56: Global Market Value (USD Million) (2025-2032) By Types

Table 57: Global Market Share (%) By Types (2032)

Table 58: Global Fragment-based Drug Discovery Market Value (USD Million) By Region

Table 59: Global Fragment-based Drug Discovery Market Share (%) By Region (2025-2032)

Table 60: North America Market Value (USD Million) (2025-2032) By Country

Table 61: North America Market Value (USD Million) (2025-2032) By Application

Table 62: North America Market Value (USD Million) (2025-2032) By Types

Table 63: Europe Market Value (USD Million) (2025-2032) By Country

Table 64: Europe Market Value (USD Million) (2025-2032) By Application

Table 65: Europe Market Value (USD Million) (2025-2032) By Types

Table 66: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 67: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 68: Asia Pacific Market Value (USD Million) (2025-2032) By Types

Table 69: South America Market Value (USD Million) (2025-2032) By Country

Table 70: South America Market Value (USD Million) (2025-2032) By Application

Table 71: South America Market Value (USD Million) (2025-2032) By Types

Table 72: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 73: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 74: Middle East & Africa Market Value (USD Million) (2025-2032) By Types

Table 75: Research Programs/Design For This Report

Table 76: Key Data Information From Secondary Sources

Table 77: Key Data Information From Primary Sources

Contact for Full Report

Loading report content...

Fragment-based Drug Discovery Market Overview

Loading chart…

Report Overview

Report Attribute	Details
Market size value in 2025	1.23 billion
Revenue forecast in 2033	2.68 billion
Growth rate	CAGR of 10.2% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Astex Pharmaceuticals; Alveus Pharmaceuticals; Beactica; Charles River Laboratories; Crown Bioscience; Emerald BioStructures; Evotec; Kinetic Discovery; Proteros Fragments; Sprint Bioscience; Structure Based Design; Sygnature Discovery
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

Growth Drivers2 items

Restraints2 items

Opportunities2 items

Challenges2 items

Market Segmentation

Loading chart…

Fragment-based Drug Discovery Segmentation Breakdown7 items

Application

Academic and Research Institutions

Biopharmaceutical Companies

Contract Research Organizations (CROs)

Types

Fragment Screening

Fragment Optimization

Regional Insights

Loading chart…

Competitive Landscape

Astex Pharmaceuticals: regional expansion

Beactica: innovation pipeline

Charles River Laboratories: vertical integration

Crown Bioscience: premium pricing

Evotec: OEM tie-ups

Proteros Fragments: local manufacturing

Key Fragment-based Drug Discovery Companies12 items

Astex Pharmaceuticals

Alveus Pharmaceuticals

Beactica

Charles River Laboratories

Crown Bioscience

Emerald BioStructures

Evotec

Kinetic Discovery

Proteros Fragments

Sprint Bioscience

Structure Based Design

Sygnature Discovery

Market Ecosystem

Technology providers — develop fragment-based drug discovery platforms

Raw material/component suppliers — provide chemical compounds and reagents

System integrators / EPCs — integrate fragment-based drug discovery technologies

Distributors / channel partners — supply fragment-based drug discovery products and services

Service providers / after-sales — offer support and maintenance for fragment-based drug discovery systems

End users / buyers — utilize fragment-based drug discovery technologies for research and development

Regulators/standards bodies — establish guidelines and standards for fragment-based drug discovery

Recent Industry Insights

Analyst Overview

Table of Contents